Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma

Clin Lung Cancer. 2019 Jul;20(4):e489-e491. doi: 10.1016/j.cllc.2019.04.007. Epub 2019 Apr 19.

¹ Division of Hematology/Oncology, Department of Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA.
² Department of Pathology, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA.
³ Department of Ophthalmology, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA.
⁴ Division of Pulmonary Medicine, Department of Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA.
⁵ Department of Neurology, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA.
⁶ Division of Hematology/Oncology, Department of Medicine, University of California Davis School of Medicine, University of California Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address: jwriess@ucdavis.edu.

No abstract available

Keywords: Immune-related adverse events; Immunotherapy; Myasthenia gravis; NSCLC; Thymoma.

Publication types